Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective
Continued advances in microarray patch (MAP) technology are starting to make needle-free delivery of a broad range of vaccines an achievable goal. The drivers and potential benefits of a MAP platform for pandemic response and routine vaccination are clear and include dose-sparing, cold-chain elimina...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2050123 |
| _version_ | 1797673181627023360 |
|---|---|
| author | Angus Forster Michael Junger |
| author_facet | Angus Forster Michael Junger |
| author_sort | Angus Forster |
| collection | DOAJ |
| description | Continued advances in microarray patch (MAP) technology are starting to make needle-free delivery of a broad range of vaccines an achievable goal. The drivers and potential benefits of a MAP platform for pandemic response and routine vaccination are clear and include dose-sparing, cold-chain elimination, increased safety, and potential self-administration. MAP technology is regarded as a priority innovation to overcome vaccination barriers, ensure equitable access, and improve the effectiveness of vaccines. Vaxxas, a global leader in this technology, has built a strong evidence-base for the commercial application of their high-density (HD) MAP platform, and is rapidly advancing scale-up of the manufacturing process for HD-MAPs. A greater awareness and understanding of the implications of the technology amongst supply-chain participants, regulatory authorities, and global healthcare organizations and foundations is needed to accelerate adoption and, particularly, to prepare for MAP use in pandemics. Key challenges remain in the commercialization of MAP technology and its adoption, including market acceptance, scale-up of production, regulatory approval, and the availability of capital to build advanced manufacturing infrastructure ahead of late-stage clinical trials. |
| first_indexed | 2024-03-11T21:41:19Z |
| format | Article |
| id | doaj.art-094c7ab7abf94f23884f8518228036b4 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:19Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-094c7ab7abf94f23884f8518228036b42023-09-26T13:19:05ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118410.1080/21645515.2022.20501232050123Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspectiveAngus Forster0Michael Junger1Vaxxas Pty LtdVaxxas Pty LtdContinued advances in microarray patch (MAP) technology are starting to make needle-free delivery of a broad range of vaccines an achievable goal. The drivers and potential benefits of a MAP platform for pandemic response and routine vaccination are clear and include dose-sparing, cold-chain elimination, increased safety, and potential self-administration. MAP technology is regarded as a priority innovation to overcome vaccination barriers, ensure equitable access, and improve the effectiveness of vaccines. Vaxxas, a global leader in this technology, has built a strong evidence-base for the commercial application of their high-density (HD) MAP platform, and is rapidly advancing scale-up of the manufacturing process for HD-MAPs. A greater awareness and understanding of the implications of the technology amongst supply-chain participants, regulatory authorities, and global healthcare organizations and foundations is needed to accelerate adoption and, particularly, to prepare for MAP use in pandemics. Key challenges remain in the commercialization of MAP technology and its adoption, including market acceptance, scale-up of production, regulatory approval, and the availability of capital to build advanced manufacturing infrastructure ahead of late-stage clinical trials.http://dx.doi.org/10.1080/21645515.2022.2050123microarray patchmapvaccine deliveryneedle-freepandemic preparednesspandemic responsevaccineinfluenza |
| spellingShingle | Angus Forster Michael Junger Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective Human Vaccines & Immunotherapeutics microarray patch map vaccine delivery needle-free pandemic preparedness pandemic response vaccine influenza |
| title | Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective |
| title_full | Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective |
| title_fullStr | Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective |
| title_full_unstemmed | Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective |
| title_short | Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective |
| title_sort | opportunities and challenges for commercializing microarray patches for vaccination from a map developer s perspective |
| topic | microarray patch map vaccine delivery needle-free pandemic preparedness pandemic response vaccine influenza |
| url | http://dx.doi.org/10.1080/21645515.2022.2050123 |
| work_keys_str_mv | AT angusforster opportunitiesandchallengesforcommercializingmicroarraypatchesforvaccinationfromamapdevelopersperspective AT michaeljunger opportunitiesandchallengesforcommercializingmicroarraypatchesforvaccinationfromamapdevelopersperspective |